| 查看: 2650 | 回复: 8 | |||||||
痴梦潇湘木虫 (著名写手)
|
[交流]
恒瑞2010-2012临床试验进展情况（共申请17项临床，其中两项已宣告失败） 已有5人参与
|
|
共有四个替尼类药物进入临床，其中阿帕替尼进入临床III期，氟马替尼进入临床II期，西帕替尼和海那替尼在临床I期被淘汰出局。 具体情况如下： Apatinib阿帕替尼 NCT01531777 (Phase 2) First received: July 20, 2010 Status: Recruiting Condition: Metastatic Breast Cancer NCT01192971 (Phase 2) First received: August 30, 2010 Status: Unknown Condition: Advanced Hepatocellular Carcinoma NCT01270386 (Phase 2) First received: December 29, 2010 Status: Completed Condition: Non-Small-Cell Lung Cancer NCT01512745 (Phase 3) First received: January 13, 2012 Status: Recruiting Condition: Advanced or Metastatic Gastric Cancer NCT01531777 (Phase 2) First received: February 7, 2012 Status: Recruiting Condition: Colorectal Cancer NCT01653561 (Phase 2) First received: July 10, 2012 Status: Recruiting Condition: Breast Neoplasms Flumatinib氟马替尼 NCT01392235 (Phase 2) First received: July 3, 2011 Status: Recruiting Condition: Recurrent and/or Metastatic Nasopharyngeal Carcinoma NCT01462474 (Phase 1) First received: October 27, 2011 Status: Recruiting Condition: Locally Advanced Nasopharyngeal Carcinoma NCT01503502 (Phase 2) First received: January 1, 2012 Status: Active, not recruiting Condition: Chronic Myelogenous Leukemia NCT01762293 (Phase 2) First received: January 4, 2013 Status: Recruiting Condition: Advanced Colorectal Cancer NCT01653574 (Phase 2) First received: July 10, 2012 Status: Recruiting Condition: Breast Neoplasms NCT01762280 (Phase 1) First received: December 26, 2012 Status: Active, not recruiting Condition: Advanced Solid Tumor Pegylated rhG-CSF重组人粒细胞集落刺激因子 NCT01560195 (Phase 3) First received: March 8, 2012 Status: Recruiting Condition: Non-Small-Cell Lung Cancer, Neutropenia, Febrile Neutropenia NCT01611051 (Phase 3) First received: May 31, 2012 Status: Completed Condition: Breast Cancer, Neutropenia, Febrile Neutropenia Tolvaptan托伐普坦 NCT01507727 (Phase 2) First received: January 5, 2012 Status: Recruiting Condition: Non-hypovolemic Non-acute Hyponatremia Cipatinib西帕替尼 NCT01301911 (Phase 1) First received: January 28, 2011 Status: Terminated Condition: Breast Cancer Henatinib海那替尼 NCT01416623 (Phase 1) First received: August 12, 2011 Status: Terminated Condition: Advanced Solid Cancer |
回复此楼» 收录本帖的淘帖专辑推荐
 新药研发 | 工作 | 注册 | 收藏 |
» 本帖已获得的红花（最新10朵）
aiyixiang» 猜你喜欢
211高校2026年入学博士名额
已经有16人回复
-
海勃原辅料助力银屑病一线外用制剂开发
已经有0人回复
-
药物学论文润色/翻译怎么收费?
已经有88人回复
-
二乙烯基砜的合成路径
已经有4人回复
-
求一株[b]敲除MTAP(human)的HCT-116(人结肠癌细胞)/b]细胞
已经有0人回复
-
这个自发加氧反应的机理是什么？
已经有7人回复
-
求助！求美国食品化学药典内容：FCC13【低聚果糖专论】
已经有0人回复
-
【2027博士申请】纳米药物递送方向
已经有5人回复
-
消耗微量API，便可预测早期研发阶段的HME工艺可行性
已经有0人回复
-
反应液中苯酐除去
已经有1人回复
beautydrug
木虫 (正式写手)
- 应助: 14 (小学生)
- 金币: 1848.8
- 红花: 2
- 帖子: 314
- 在线: 190.5小时
- 虫号: 1582078
- 注册: 2012-01-18
- 性别: GG
- 专业: 药物设计与药物信息
2楼2013-01-14 08:54:20
qxm2005
木虫 (著名写手)
- 应助: 50 (小学生)
- 金币: 3947.3
- 散金: 145
- 红花: 14
- 帖子: 2357
- 在线: 2251.2小时
- 虫号: 1621098
- 注册: 2012-02-16
- 性别: GG
- 专业: 生物化工与食品化工
3楼2013-01-14 11:01:19
wobaby
铁虫 (著名写手)
- 应助: 7 (幼儿园)
- 金币: 13
- 散金: 308
- 沙发: 3
- 帖子: 1517
- 在线: 550.2小时
- 虫号: 551938
- 注册: 2008-04-28
- 性别: GG
- 专业: 肿瘤综合治疗
4楼2013-01-14 22:21:06
痴梦潇湘
木虫 (著名写手)
- 应助: 16 (小学生)
- 金币: 3897.3
- 散金: 2200
- 红花: 107
- 沙发: 8
- 帖子: 2857
- 在线: 1192.5小时
- 虫号: 1120792
- 注册: 2010-10-12
- 性别: GG
- 专业: 药物化学
5楼2013-01-14 22:41:06
6楼2013-01-16 12:35:07
cnlics
木虫 (小有名气)
- 应助: 2 (幼儿园)
- 金币: 3014.2
- 红花: 4
- 帖子: 270
- 在线: 422.4小时
- 虫号: 795158
- 注册: 2009-06-16
- 性别: GG
- 专业: 当代宗教
7楼2013-01-16 14:28:00
wobaby
铁虫 (著名写手)
- 应助: 7 (幼儿园)
- 金币: 13
- 散金: 308
- 沙发: 3
- 帖子: 1517
- 在线: 550.2小时
- 虫号: 551938
- 注册: 2008-04-28
- 性别: GG
- 专业: 肿瘤综合治疗
8楼2013-01-16 23:10:10
痴梦潇湘
木虫 (著名写手)
- 应助: 16 (小学生)
- 金币: 3897.3
- 散金: 2200
- 红花: 107
- 沙发: 8
- 帖子: 2857
- 在线: 1192.5小时
- 虫号: 1120792
- 注册: 2010-10-12
- 性别: GG
- 专业: 药物化学
9楼2013-01-16 23:44:01
20